nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranitidine—CYP3A5—Beclomethasone—psoriasis	0.0795	0.105	CbGbCtD
Ranitidine—CYP1A2—Clobetasol propionate—psoriasis	0.0781	0.103	CbGbCtD
Ranitidine—CYP1A2—Methoxsalen—psoriasis	0.041	0.0543	CbGbCtD
Ranitidine—CYP2D6—Hydroxyurea—psoriasis	0.0369	0.0489	CbGbCtD
Ranitidine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0316	0.0419	CbGbCtD
Ranitidine—CYP2C19—Cholecalciferol—psoriasis	0.0294	0.039	CbGbCtD
Ranitidine—CYP3A4—Calcitriol—psoriasis	0.0276	0.0366	CbGbCtD
Ranitidine—SLC22A8—Methotrexate—psoriasis	0.0266	0.0353	CbGbCtD
Ranitidine—CYP3A5—Hydrocortisone—psoriasis	0.0254	0.0336	CbGbCtD
Ranitidine—CYP3A5—Cyclosporine—psoriasis	0.024	0.0318	CbGbCtD
Ranitidine—CYP2D6—Cholecalciferol—psoriasis	0.0224	0.0297	CbGbCtD
Ranitidine—CYP3A4—Methoxsalen—psoriasis	0.0215	0.0285	CbGbCtD
Ranitidine—ABCB1—Mycophenolate mofetil—psoriasis	0.0206	0.0273	CbGbCtD
Ranitidine—CYP2C19—Prednisone—psoriasis	0.0204	0.027	CbGbCtD
Ranitidine—CYP2C19—Cyclosporine—psoriasis	0.0193	0.0256	CbGbCtD
Ranitidine—ABCB1—Betamethasone—psoriasis	0.0177	0.0234	CbGbCtD
Ranitidine—ABCB1—Prednisolone—psoriasis	0.0174	0.0231	CbGbCtD
Ranitidine—ABCB1—Hydrocortisone—psoriasis	0.0165	0.0219	CbGbCtD
Ranitidine—ABCB1—Prednisone—psoriasis	0.0165	0.0218	CbGbCtD
Ranitidine—CYP3A5—Dexamethasone—psoriasis	0.0158	0.0209	CbGbCtD
Ranitidine—ABCB1—Cyclosporine—psoriasis	0.0156	0.0207	CbGbCtD
Ranitidine—CYP2D6—Cyclosporine—psoriasis	0.0147	0.0195	CbGbCtD
Ranitidine—CYP3A4—Cholecalciferol—psoriasis	0.0142	0.0189	CbGbCtD
Ranitidine—CYP2C19—Dexamethasone—psoriasis	0.0127	0.0169	CbGbCtD
Ranitidine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0123	0.0163	CbGbCtD
Ranitidine—CYP3A4—Triamcinolone—psoriasis	0.0123	0.0163	CbGbCtD
Ranitidine—CYP3A4—Betamethasone—psoriasis	0.0106	0.014	CbGbCtD
Ranitidine—CYP3A4—Prednisolone—psoriasis	0.0104	0.0138	CbGbCtD
Ranitidine—ABCB1—Dexamethasone—psoriasis	0.0103	0.0136	CbGbCtD
Ranitidine—CYP3A4—Hydrocortisone—psoriasis	0.0099	0.0131	CbGbCtD
Ranitidine—CYP3A4—Prednisone—psoriasis	0.00987	0.0131	CbGbCtD
Ranitidine—CYP2D6—Dexamethasone—psoriasis	0.00969	0.0128	CbGbCtD
Ranitidine—CYP3A4—Cyclosporine—psoriasis	0.00935	0.0124	CbGbCtD
Ranitidine—ABCB1—Methotrexate—psoriasis	0.00826	0.0109	CbGbCtD
Ranitidine—CYP3A4—Dexamethasone—psoriasis	0.00616	0.00816	CbGbCtD
Ranitidine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000603	0.062	CbGpPWpGaD
Ranitidine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000555	0.057	CbGpPWpGaD
Ranitidine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000517	0.0532	CbGpPWpGaD
Ranitidine—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000484	0.0497	CbGpPWpGaD
Ranitidine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000374	0.0384	CbGpPWpGaD
Ranitidine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000344	0.0353	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000293	0.0301	CbGpPWpGaD
Ranitidine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000291	0.0299	CbGpPWpGaD
Ranitidine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000225	0.0231	CbGpPWpGaD
Ranitidine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000201	0.0206	CbGpPWpGaD
Ranitidine—Pancreatitis—Methotrexate—psoriasis	0.000199	0.000844	CcSEcCtD
Ranitidine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000199	0.000843	CcSEcCtD
Ranitidine—Ill-defined disorder—Triamcinolone—psoriasis	0.000198	0.000843	CcSEcCtD
Ranitidine—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000198	0.0204	CbGpPWpGaD
Ranitidine—Bradycardia—Prednisone—psoriasis	0.000198	0.000839	CcSEcCtD
Ranitidine—Alopecia—Betamethasone—psoriasis	0.000197	0.000837	CcSEcCtD
Ranitidine—Alopecia—Dexamethasone—psoriasis	0.000197	0.000837	CcSEcCtD
Ranitidine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000197	0.000835	CcSEcCtD
Ranitidine—Vomiting—Hydroxyurea—psoriasis	0.000196	0.000831	CcSEcCtD
Ranitidine—Discomfort—Prednisolone—psoriasis	0.000196	0.000831	CcSEcCtD
Ranitidine—Angioedema—Triamcinolone—psoriasis	0.000195	0.00083	CcSEcCtD
Ranitidine—Abdominal discomfort—Methotrexate—psoriasis	0.000194	0.000825	CcSEcCtD
Ranitidine—Rash—Hydroxyurea—psoriasis	0.000194	0.000824	CcSEcCtD
Ranitidine—Erythema—Betamethasone—psoriasis	0.000194	0.000824	CcSEcCtD
Ranitidine—Erythema—Dexamethasone—psoriasis	0.000194	0.000824	CcSEcCtD
Ranitidine—Dermatitis—Hydroxyurea—psoriasis	0.000194	0.000824	CcSEcCtD
Ranitidine—Myalgia—Hydrocortisone—psoriasis	0.000193	0.000821	CcSEcCtD
Ranitidine—Hallucination—Prednisone—psoriasis	0.000193	0.00082	CcSEcCtD
Ranitidine—Malaise—Triamcinolone—psoriasis	0.000193	0.000819	CcSEcCtD
Ranitidine—Headache—Hydroxyurea—psoriasis	0.000193	0.000819	CcSEcCtD
Ranitidine—Pancytopenia—Methotrexate—psoriasis	0.000192	0.000818	CcSEcCtD
Ranitidine—Vertigo—Triamcinolone—psoriasis	0.000192	0.000816	CcSEcCtD
Ranitidine—Discomfort—Hydrocortisone—psoriasis	0.000191	0.000811	CcSEcCtD
Ranitidine—Hypotension—Mycophenolate mofetil—psoriasis	0.00019	0.000808	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.00019	0.000807	CcSEcCtD
Ranitidine—Anaphylactic shock—Prednisolone—psoriasis	0.00019	0.000806	CcSEcCtD
Ranitidine—Neutropenia—Methotrexate—psoriasis	0.000189	0.000805	CcSEcCtD
Ranitidine—Insomnia—Cyclosporine—psoriasis	0.000189	0.000801	CcSEcCtD
Ranitidine—Erectile dysfunction—Methotrexate—psoriasis	0.000187	0.000793	CcSEcCtD
Ranitidine—Dyspnoea—Cyclosporine—psoriasis	0.000186	0.00079	CcSEcCtD
Ranitidine—Somnolence—Cyclosporine—psoriasis	0.000185	0.000788	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000185	0.000787	CcSEcCtD
Ranitidine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000185	0.000787	CcSEcCtD
Ranitidine—Tachycardia—Prednisolone—psoriasis	0.000185	0.000787	CcSEcCtD
Ranitidine—Photosensitivity reaction—Methotrexate—psoriasis	0.000185	0.000786	CcSEcCtD
Ranitidine—Insomnia—Mycophenolate mofetil—psoriasis	0.000184	0.000782	CcSEcCtD
Ranitidine—Hyperhidrosis—Prednisolone—psoriasis	0.000183	0.000779	CcSEcCtD
Ranitidine—Nausea—Hydroxyurea—psoriasis	0.000183	0.000777	CcSEcCtD
Ranitidine—Pruritus—Mycophenolic acid—psoriasis	0.000182	0.000775	CcSEcCtD
Ranitidine—Myalgia—Triamcinolone—psoriasis	0.000182	0.000773	CcSEcCtD
Ranitidine—Pneumonia—Methotrexate—psoriasis	0.000182	0.000772	CcSEcCtD
Ranitidine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000181	0.00077	CcSEcCtD
Ranitidine—Tachycardia—Hydrocortisone—psoriasis	0.000181	0.000768	CcSEcCtD
Ranitidine—Somnolence—Mycophenolate mofetil—psoriasis	0.000181	0.000768	CcSEcCtD
Ranitidine—Ill-defined disorder—Betamethasone—psoriasis	0.00018	0.000765	CcSEcCtD
Ranitidine—Ill-defined disorder—Dexamethasone—psoriasis	0.00018	0.000765	CcSEcCtD
Ranitidine—Discomfort—Triamcinolone—psoriasis	0.00018	0.000764	CcSEcCtD
Ranitidine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000179	0.000761	CcSEcCtD
Ranitidine—Pain—Cyclosporine—psoriasis	0.000178	0.000758	CcSEcCtD
Ranitidine—Constipation—Cyclosporine—psoriasis	0.000178	0.000758	CcSEcCtD
Ranitidine—Angioedema—Betamethasone—psoriasis	0.000177	0.000753	CcSEcCtD
Ranitidine—Angioedema—Dexamethasone—psoriasis	0.000177	0.000753	CcSEcCtD
Ranitidine—Diarrhoea—Mycophenolic acid—psoriasis	0.000176	0.000749	CcSEcCtD
Ranitidine—Malaise—Betamethasone—psoriasis	0.000175	0.000743	CcSEcCtD
Ranitidine—Malaise—Dexamethasone—psoriasis	0.000175	0.000743	CcSEcCtD
Ranitidine—Anaphylactic shock—Triamcinolone—psoriasis	0.000174	0.000741	CcSEcCtD
Ranitidine—Vertigo—Betamethasone—psoriasis	0.000174	0.000741	CcSEcCtD
Ranitidine—Vertigo—Dexamethasone—psoriasis	0.000174	0.000741	CcSEcCtD
Ranitidine—Constipation—Mycophenolate mofetil—psoriasis	0.000174	0.000739	CcSEcCtD
Ranitidine—Pain—Mycophenolate mofetil—psoriasis	0.000174	0.000739	CcSEcCtD
Ranitidine—Arrhythmia—Prednisone—psoriasis	0.000173	0.000737	CcSEcCtD
Ranitidine—Sweating—Methotrexate—psoriasis	0.000173	0.000736	CcSEcCtD
Ranitidine—Hypotension—Hydrocortisone—psoriasis	0.000173	0.000736	CcSEcCtD
Ranitidine—Feeling abnormal—Cyclosporine—psoriasis	0.000172	0.00073	CcSEcCtD
Ranitidine—Insomnia—Prednisolone—psoriasis	0.000172	0.000729	CcSEcCtD
Ranitidine—Alopecia—Prednisone—psoriasis	0.000171	0.000729	CcSEcCtD
Ranitidine—Dizziness—Mycophenolic acid—psoriasis	0.00017	0.000724	CcSEcCtD
Ranitidine—Tachycardia—Triamcinolone—psoriasis	0.00017	0.000724	CcSEcCtD
Ranitidine—Erythema—Prednisone—psoriasis	0.000169	0.000718	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000169	0.000717	CcSEcCtD
Ranitidine—Hyperhidrosis—Triamcinolone—psoriasis	0.000169	0.000717	CcSEcCtD
Ranitidine—Agranulocytosis—Methotrexate—psoriasis	0.000169	0.000716	CcSEcCtD
Ranitidine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000168	0.000712	CcSEcCtD
Ranitidine—Insomnia—Hydrocortisone—psoriasis	0.000168	0.000712	CcSEcCtD
Ranitidine—Urticaria—Cyclosporine—psoriasis	0.000166	0.000704	CcSEcCtD
Ranitidine—Myalgia—Betamethasone—psoriasis	0.000165	0.000702	CcSEcCtD
Ranitidine—Myalgia—Dexamethasone—psoriasis	0.000165	0.000702	CcSEcCtD
Ranitidine—Abdominal pain—Cyclosporine—psoriasis	0.000165	0.0007	CcSEcCtD
Ranitidine—Body temperature increased—Cyclosporine—psoriasis	0.000165	0.0007	CcSEcCtD
Ranitidine—Vomiting—Mycophenolic acid—psoriasis	0.000164	0.000696	CcSEcCtD
Ranitidine—Discomfort—Betamethasone—psoriasis	0.000163	0.000693	CcSEcCtD
Ranitidine—Discomfort—Dexamethasone—psoriasis	0.000163	0.000693	CcSEcCtD
Ranitidine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000163	0.0167	CbGpPWpGaD
Ranitidine—Rash—Mycophenolic acid—psoriasis	0.000162	0.00069	CcSEcCtD
Ranitidine—Dermatitis—Mycophenolic acid—psoriasis	0.000162	0.00069	CcSEcCtD
Ranitidine—Pain—Prednisolone—psoriasis	0.000162	0.000689	CcSEcCtD
Ranitidine—Hepatitis—Methotrexate—psoriasis	0.000162	0.000689	CcSEcCtD
Ranitidine—Urticaria—Mycophenolate mofetil—psoriasis	0.000162	0.000687	CcSEcCtD
Ranitidine—Headache—Mycophenolic acid—psoriasis	0.000161	0.000686	CcSEcCtD
Ranitidine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000161	0.000683	CcSEcCtD
Ranitidine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000161	0.000683	CcSEcCtD
Ranitidine—Vision blurred—Prednisone—psoriasis	0.000159	0.000676	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000159	0.000675	CcSEcCtD
Ranitidine—Pain—Hydrocortisone—psoriasis	0.000158	0.000673	CcSEcCtD
Ranitidine—Anaphylactic shock—Dexamethasone—psoriasis	0.000158	0.000673	CcSEcCtD
Ranitidine—Anaphylactic shock—Betamethasone—psoriasis	0.000158	0.000673	CcSEcCtD
Ranitidine—Insomnia—Triamcinolone—psoriasis	0.000158	0.000671	CcSEcCtD
Ranitidine—Ill-defined disorder—Prednisone—psoriasis	0.000157	0.000666	CcSEcCtD
Ranitidine—Feeling abnormal—Prednisolone—psoriasis	0.000156	0.000664	CcSEcCtD
Ranitidine—Anaemia—Prednisone—psoriasis	0.000156	0.000663	CcSEcCtD
Ranitidine—Dyspnoea—Triamcinolone—psoriasis	0.000156	0.000661	CcSEcCtD
Ranitidine—Agitation—Prednisone—psoriasis	0.000155	0.00066	CcSEcCtD
Ranitidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000155	0.0159	CbGpPWpGaD
Ranitidine—Thrombocytopenia—Dexamethasone—psoriasis	0.000155	0.000659	CcSEcCtD
Ranitidine—Thrombocytopenia—Betamethasone—psoriasis	0.000155	0.000659	CcSEcCtD
Ranitidine—Tachycardia—Dexamethasone—psoriasis	0.000155	0.000657	CcSEcCtD
Ranitidine—Tachycardia—Betamethasone—psoriasis	0.000155	0.000657	CcSEcCtD
Ranitidine—Angioedema—Prednisone—psoriasis	0.000154	0.000656	CcSEcCtD
Ranitidine—Hypersensitivity—Cyclosporine—psoriasis	0.000154	0.000653	CcSEcCtD
Ranitidine—Erythema multiforme—Methotrexate—psoriasis	0.000153	0.000652	CcSEcCtD
Ranitidine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000153	0.0157	CbGpPWpGaD
Ranitidine—Nausea—Mycophenolic acid—psoriasis	0.000153	0.00065	CcSEcCtD
Ranitidine—Hyperhidrosis—Betamethasone—psoriasis	0.000153	0.00065	CcSEcCtD
Ranitidine—Hyperhidrosis—Dexamethasone—psoriasis	0.000153	0.00065	CcSEcCtD
Ranitidine—Feeling abnormal—Hydrocortisone—psoriasis	0.000153	0.000649	CcSEcCtD
Ranitidine—Malaise—Prednisone—psoriasis	0.000152	0.000647	CcSEcCtD
Ranitidine—Vertigo—Prednisone—psoriasis	0.000152	0.000645	CcSEcCtD
Ranitidine—Urticaria—Prednisolone—psoriasis	0.000151	0.00064	CcSEcCtD
Ranitidine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00015	0.000637	CcSEcCtD
Ranitidine—Pain—Triamcinolone—psoriasis	0.000149	0.000634	CcSEcCtD
Ranitidine—Hypotension—Dexamethasone—psoriasis	0.000148	0.000629	CcSEcCtD
Ranitidine—Hypotension—Betamethasone—psoriasis	0.000148	0.000629	CcSEcCtD
Ranitidine—Pruritus—Cyclosporine—psoriasis	0.000148	0.000627	CcSEcCtD
Ranitidine—Urticaria—Hydrocortisone—psoriasis	0.000147	0.000625	CcSEcCtD
Ranitidine—Body temperature increased—Hydrocortisone—psoriasis	0.000146	0.000622	CcSEcCtD
Ranitidine—Abdominal pain—Hydrocortisone—psoriasis	0.000146	0.000622	CcSEcCtD
Ranitidine—HRH2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000145	0.0149	CbGpPWpGaD
Ranitidine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000144	0.000613	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000144	0.000613	CcSEcCtD
Ranitidine—Pruritus—Mycophenolate mofetil—psoriasis	0.000144	0.000611	CcSEcCtD
Ranitidine—Myalgia—Prednisone—psoriasis	0.000144	0.000611	CcSEcCtD
Ranitidine—Arthralgia—Prednisone—psoriasis	0.000144	0.000611	CcSEcCtD
Ranitidine—Feeling abnormal—Triamcinolone—psoriasis	0.000144	0.000611	CcSEcCtD
Ranitidine—Alopecia—Methotrexate—psoriasis	0.000143	0.000609	CcSEcCtD
Ranitidine—Insomnia—Betamethasone—psoriasis	0.000143	0.000608	CcSEcCtD
Ranitidine—Insomnia—Dexamethasone—psoriasis	0.000143	0.000608	CcSEcCtD
Ranitidine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000143	0.0147	CbGpPWpGaD
Ranitidine—Diarrhoea—Cyclosporine—psoriasis	0.000143	0.000606	CcSEcCtD
Ranitidine—Discomfort—Prednisone—psoriasis	0.000142	0.000604	CcSEcCtD
Ranitidine—Erythema—Methotrexate—psoriasis	0.000141	0.0006	CcSEcCtD
Ranitidine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000141	0.0145	CbGpPWpGaD
Ranitidine—Hypersensitivity—Prednisolone—psoriasis	0.00014	0.000594	CcSEcCtD
Ranitidine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000139	0.000591	CcSEcCtD
Ranitidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000139	0.0143	CbGpPWpGaD
Ranitidine—Urticaria—Triamcinolone—psoriasis	0.000139	0.000589	CcSEcCtD
Ranitidine—Body temperature increased—Triamcinolone—psoriasis	0.000138	0.000586	CcSEcCtD
Ranitidine—Dizziness—Cyclosporine—psoriasis	0.000138	0.000586	CcSEcCtD
Ranitidine—Anaphylactic shock—Prednisone—psoriasis	0.000138	0.000586	CcSEcCtD
Ranitidine—Hypersensitivity—Hydrocortisone—psoriasis	0.000137	0.00058	CcSEcCtD
Ranitidine—Pain—Betamethasone—psoriasis	0.000135	0.000575	CcSEcCtD
Ranitidine—Pain—Dexamethasone—psoriasis	0.000135	0.000575	CcSEcCtD
Ranitidine—Tachycardia—Prednisone—psoriasis	0.000135	0.000572	CcSEcCtD
Ranitidine—Dizziness—Mycophenolate mofetil—psoriasis	0.000134	0.000571	CcSEcCtD
Ranitidine—Hyperhidrosis—Prednisone—psoriasis	0.000133	0.000566	CcSEcCtD
Ranitidine—Vision blurred—Methotrexate—psoriasis	0.000133	0.000565	CcSEcCtD
Ranitidine—Vomiting—Cyclosporine—psoriasis	0.000133	0.000563	CcSEcCtD
Ranitidine—Rash—Cyclosporine—psoriasis	0.000131	0.000559	CcSEcCtD
Ranitidine—Dermatitis—Cyclosporine—psoriasis	0.000131	0.000558	CcSEcCtD
Ranitidine—Pruritus—Hydrocortisone—psoriasis	0.000131	0.000557	CcSEcCtD
Ranitidine—Ill-defined disorder—Methotrexate—psoriasis	0.000131	0.000557	CcSEcCtD
Ranitidine—Headache—Cyclosporine—psoriasis	0.000131	0.000555	CcSEcCtD
Ranitidine—Anaemia—Methotrexate—psoriasis	0.00013	0.000554	CcSEcCtD
Ranitidine—Feeling abnormal—Dexamethasone—psoriasis	0.00013	0.000554	CcSEcCtD
Ranitidine—Feeling abnormal—Betamethasone—psoriasis	0.00013	0.000554	CcSEcCtD
Ranitidine—Vomiting—Mycophenolate mofetil—psoriasis	0.000129	0.000549	CcSEcCtD
Ranitidine—Hypersensitivity—Triamcinolone—psoriasis	0.000129	0.000546	CcSEcCtD
Ranitidine—Rash—Mycophenolate mofetil—psoriasis	0.000128	0.000545	CcSEcCtD
Ranitidine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000128	0.000544	CcSEcCtD
Ranitidine—Headache—Mycophenolate mofetil—psoriasis	0.000127	0.000541	CcSEcCtD
Ranitidine—Malaise—Methotrexate—psoriasis	0.000127	0.000541	CcSEcCtD
Ranitidine—Vertigo—Methotrexate—psoriasis	0.000127	0.000539	CcSEcCtD
Ranitidine—Diarrhoea—Hydrocortisone—psoriasis	0.000127	0.000539	CcSEcCtD
Ranitidine—Leukopenia—Methotrexate—psoriasis	0.000126	0.000537	CcSEcCtD
Ranitidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000126	0.0129	CbGpPWpGaD
Ranitidine—Urticaria—Betamethasone—psoriasis	0.000126	0.000534	CcSEcCtD
Ranitidine—Urticaria—Dexamethasone—psoriasis	0.000126	0.000534	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Prednisone—psoriasis	0.000126	0.000534	CcSEcCtD
Ranitidine—Dizziness—Prednisolone—psoriasis	0.000125	0.000533	CcSEcCtD
Ranitidine—Abdominal pain—Dexamethasone—psoriasis	0.000125	0.000532	CcSEcCtD
Ranitidine—Abdominal pain—Betamethasone—psoriasis	0.000125	0.000532	CcSEcCtD
Ranitidine—Body temperature increased—Betamethasone—psoriasis	0.000125	0.000532	CcSEcCtD
Ranitidine—Body temperature increased—Dexamethasone—psoriasis	0.000125	0.000532	CcSEcCtD
Ranitidine—Insomnia—Prednisone—psoriasis	0.000125	0.00053	CcSEcCtD
Ranitidine—Nausea—Cyclosporine—psoriasis	0.000124	0.000526	CcSEcCtD
Ranitidine—Pruritus—Triamcinolone—psoriasis	0.000123	0.000525	CcSEcCtD
Ranitidine—Dizziness—Hydrocortisone—psoriasis	0.000123	0.000521	CcSEcCtD
Ranitidine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000121	0.0124	CbGpPWpGaD
Ranitidine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000121	0.0124	CbGpPWpGaD
Ranitidine—Nausea—Mycophenolate mofetil—psoriasis	0.000121	0.000513	CcSEcCtD
Ranitidine—Myalgia—Methotrexate—psoriasis	0.00012	0.000511	CcSEcCtD
Ranitidine—Chest pain—Methotrexate—psoriasis	0.00012	0.000511	CcSEcCtD
Ranitidine—Arthralgia—Methotrexate—psoriasis	0.00012	0.000511	CcSEcCtD
Ranitidine—Rash—Prednisolone—psoriasis	0.00012	0.000508	CcSEcCtD
Ranitidine—Dermatitis—Prednisolone—psoriasis	0.00012	0.000508	CcSEcCtD
Ranitidine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000119	0.0123	CbGpPWpGaD
Ranitidine—Headache—Prednisolone—psoriasis	0.000119	0.000505	CcSEcCtD
Ranitidine—Discomfort—Methotrexate—psoriasis	0.000119	0.000505	CcSEcCtD
Ranitidine—Constipation—Prednisone—psoriasis	0.000118	0.000501	CcSEcCtD
Ranitidine—Vomiting—Hydrocortisone—psoriasis	0.000118	0.000501	CcSEcCtD
Ranitidine—Rash—Hydrocortisone—psoriasis	0.000117	0.000496	CcSEcCtD
Ranitidine—Dermatitis—Hydrocortisone—psoriasis	0.000117	0.000496	CcSEcCtD
Ranitidine—Confusional state—Methotrexate—psoriasis	0.000116	0.000494	CcSEcCtD
Ranitidine—Headache—Hydrocortisone—psoriasis	0.000116	0.000493	CcSEcCtD
Ranitidine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000116	0.0119	CbGpPWpGaD
Ranitidine—Dizziness—Triamcinolone—psoriasis	0.000115	0.00049	CcSEcCtD
Ranitidine—Anaphylactic shock—Methotrexate—psoriasis	0.000115	0.00049	CcSEcCtD
Ranitidine—Feeling abnormal—Prednisone—psoriasis	0.000114	0.000483	CcSEcCtD
Ranitidine—Thrombocytopenia—Methotrexate—psoriasis	0.000113	0.000479	CcSEcCtD
Ranitidine—Nausea—Prednisolone—psoriasis	0.000113	0.000479	CcSEcCtD
Ranitidine—Pruritus—Betamethasone—psoriasis	0.000112	0.000476	CcSEcCtD
Ranitidine—Pruritus—Dexamethasone—psoriasis	0.000112	0.000476	CcSEcCtD
Ranitidine—Hyperhidrosis—Methotrexate—psoriasis	0.000111	0.000473	CcSEcCtD
Ranitidine—Vomiting—Triamcinolone—psoriasis	0.000111	0.000471	CcSEcCtD
Ranitidine—HRH2—GPCR ligand binding—HCAR2—psoriasis	0.00011	0.0113	CbGpPWpGaD
Ranitidine—Nausea—Hydrocortisone—psoriasis	0.00011	0.000468	CcSEcCtD
Ranitidine—Rash—Triamcinolone—psoriasis	0.00011	0.000467	CcSEcCtD
Ranitidine—Dermatitis—Triamcinolone—psoriasis	0.00011	0.000467	CcSEcCtD
Ranitidine—Urticaria—Prednisone—psoriasis	0.00011	0.000465	CcSEcCtD
Ranitidine—Headache—Triamcinolone—psoriasis	0.000109	0.000464	CcSEcCtD
Ranitidine—Body temperature increased—Prednisone—psoriasis	0.000109	0.000463	CcSEcCtD
Ranitidine—Abdominal pain—Prednisone—psoriasis	0.000109	0.000463	CcSEcCtD
Ranitidine—Diarrhoea—Dexamethasone—psoriasis	0.000108	0.00046	CcSEcCtD
Ranitidine—Diarrhoea—Betamethasone—psoriasis	0.000108	0.00046	CcSEcCtD
Ranitidine—Hypotension—Methotrexate—psoriasis	0.000108	0.000457	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000105	0.000446	CcSEcCtD
Ranitidine—Dizziness—Dexamethasone—psoriasis	0.000105	0.000445	CcSEcCtD
Ranitidine—Dizziness—Betamethasone—psoriasis	0.000105	0.000445	CcSEcCtD
Ranitidine—Insomnia—Methotrexate—psoriasis	0.000104	0.000443	CcSEcCtD
Ranitidine—Nausea—Triamcinolone—psoriasis	0.000104	0.00044	CcSEcCtD
Ranitidine—Dyspnoea—Methotrexate—psoriasis	0.000103	0.000436	CcSEcCtD
Ranitidine—Somnolence—Methotrexate—psoriasis	0.000102	0.000435	CcSEcCtD
Ranitidine—Hypersensitivity—Prednisone—psoriasis	0.000102	0.000432	CcSEcCtD
Ranitidine—Vomiting—Dexamethasone—psoriasis	0.000101	0.000428	CcSEcCtD
Ranitidine—Vomiting—Betamethasone—psoriasis	0.000101	0.000428	CcSEcCtD
Ranitidine—Rash—Betamethasone—psoriasis	9.98e-05	0.000424	CcSEcCtD
Ranitidine—Rash—Dexamethasone—psoriasis	9.98e-05	0.000424	CcSEcCtD
Ranitidine—Dermatitis—Dexamethasone—psoriasis	9.97e-05	0.000424	CcSEcCtD
Ranitidine—Dermatitis—Betamethasone—psoriasis	9.97e-05	0.000424	CcSEcCtD
Ranitidine—Headache—Betamethasone—psoriasis	9.92e-05	0.000421	CcSEcCtD
Ranitidine—Headache—Dexamethasone—psoriasis	9.92e-05	0.000421	CcSEcCtD
Ranitidine—Pain—Methotrexate—psoriasis	9.85e-05	0.000419	CcSEcCtD
Ranitidine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	9.81e-05	0.0101	CbGpPWpGaD
Ranitidine—Pruritus—Prednisone—psoriasis	9.75e-05	0.000414	CcSEcCtD
Ranitidine—Feeling abnormal—Methotrexate—psoriasis	9.49e-05	0.000403	CcSEcCtD
Ranitidine—Diarrhoea—Prednisone—psoriasis	9.43e-05	0.000401	CcSEcCtD
Ranitidine—Nausea—Betamethasone—psoriasis	9.4e-05	0.0004	CcSEcCtD
Ranitidine—Nausea—Dexamethasone—psoriasis	9.4e-05	0.0004	CcSEcCtD
Ranitidine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	9.33e-05	0.00959	CbGpPWpGaD
Ranitidine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	9.21e-05	0.00946	CbGpPWpGaD
Ranitidine—Urticaria—Methotrexate—psoriasis	9.15e-05	0.000389	CcSEcCtD
Ranitidine—Dizziness—Prednisone—psoriasis	9.12e-05	0.000387	CcSEcCtD
Ranitidine—Abdominal pain—Methotrexate—psoriasis	9.11e-05	0.000387	CcSEcCtD
Ranitidine—Body temperature increased—Methotrexate—psoriasis	9.11e-05	0.000387	CcSEcCtD
Ranitidine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	9.01e-05	0.00926	CbGpPWpGaD
Ranitidine—Vomiting—Prednisone—psoriasis	8.77e-05	0.000372	CcSEcCtD
Ranitidine—Rash—Prednisone—psoriasis	8.69e-05	0.000369	CcSEcCtD
Ranitidine—Dermatitis—Prednisone—psoriasis	8.68e-05	0.000369	CcSEcCtD
Ranitidine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	8.65e-05	0.00888	CbGpPWpGaD
Ranitidine—Headache—Prednisone—psoriasis	8.64e-05	0.000367	CcSEcCtD
Ranitidine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	8.53e-05	0.00876	CbGpPWpGaD
Ranitidine—Hypersensitivity—Methotrexate—psoriasis	8.49e-05	0.000361	CcSEcCtD
Ranitidine—Nausea—Prednisone—psoriasis	8.19e-05	0.000348	CcSEcCtD
Ranitidine—Pruritus—Methotrexate—psoriasis	8.15e-05	0.000346	CcSEcCtD
Ranitidine—Diarrhoea—Methotrexate—psoriasis	7.88e-05	0.000335	CcSEcCtD
Ranitidine—Dizziness—Methotrexate—psoriasis	7.62e-05	0.000324	CcSEcCtD
Ranitidine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.57e-05	0.00777	CbGpPWpGaD
Ranitidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.52e-05	0.00773	CbGpPWpGaD
Ranitidine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	7.47e-05	0.00767	CbGpPWpGaD
Ranitidine—Vomiting—Methotrexate—psoriasis	7.33e-05	0.000311	CcSEcCtD
Ranitidine—Rash—Methotrexate—psoriasis	7.26e-05	0.000309	CcSEcCtD
Ranitidine—Dermatitis—Methotrexate—psoriasis	7.26e-05	0.000308	CcSEcCtD
Ranitidine—Headache—Methotrexate—psoriasis	7.22e-05	0.000307	CcSEcCtD
Ranitidine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	7.19e-05	0.00738	CbGpPWpGaD
Ranitidine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.96e-05	0.00715	CbGpPWpGaD
Ranitidine—Nausea—Methotrexate—psoriasis	6.84e-05	0.000291	CcSEcCtD
Ranitidine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	6.68e-05	0.00687	CbGpPWpGaD
Ranitidine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	6.59e-05	0.00677	CbGpPWpGaD
Ranitidine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	6.48e-05	0.00666	CbGpPWpGaD
Ranitidine—SLC22A8—SLC-mediated transmembrane transport—CP—psoriasis	6.31e-05	0.00649	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—HCAR2—psoriasis	6.23e-05	0.0064	CbGpPWpGaD
Ranitidine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	6.15e-05	0.00632	CbGpPWpGaD
Ranitidine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	6.06e-05	0.00623	CbGpPWpGaD
Ranitidine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	5.96e-05	0.00612	CbGpPWpGaD
Ranitidine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	5.93e-05	0.00609	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	5.8e-05	0.00596	CbGpPWpGaD
Ranitidine—HRH2—GPCR ligand binding—CCL20—psoriasis	5.73e-05	0.00589	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—HCAR2—psoriasis	5.66e-05	0.00582	CbGpPWpGaD
Ranitidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.56e-05	0.00571	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—HLA-C—psoriasis	5.55e-05	0.0057	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—IL13—psoriasis	5.51e-05	0.00566	CbGpPWpGaD
Ranitidine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	5.21e-05	0.00535	CbGpPWpGaD
Ranitidine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	5.14e-05	0.00528	CbGpPWpGaD
Ranitidine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	5.13e-05	0.00527	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—IL17A—psoriasis	5.07e-05	0.00521	CbGpPWpGaD
Ranitidine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	5.05e-05	0.00519	CbGpPWpGaD
Ranitidine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.85e-05	0.00498	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—IL12B—psoriasis	4.72e-05	0.00485	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—HLA-E—psoriasis	4.6e-05	0.00473	CbGpPWpGaD
Ranitidine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	4.49e-05	0.00462	CbGpPWpGaD
Ranitidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.29e-05	0.00441	CbGpPWpGaD
Ranitidine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	4.09e-05	0.00421	CbGpPWpGaD
Ranitidine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.02e-05	0.00413	CbGpPWpGaD
Ranitidine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	3.96e-05	0.00407	CbGpPWpGaD
Ranitidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.87e-05	0.00398	CbGpPWpGaD
Ranitidine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	3.85e-05	0.00396	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.81e-05	0.00391	CbGpPWpGaD
Ranitidine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.55e-05	0.00364	CbGpPWpGaD
Ranitidine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.47e-05	0.00356	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—IL10—psoriasis	3.45e-05	0.00354	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—IL4—psoriasis	3.35e-05	0.00345	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—HCAR2—psoriasis	3.34e-05	0.00344	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.28e-05	0.00337	CbGpPWpGaD
Ranitidine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.28e-05	0.00337	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—CCL20—psoriasis	3.24e-05	0.00333	CbGpPWpGaD
Ranitidine—SLC22A8—Transmembrane transport of small molecules—CP—psoriasis	3.21e-05	0.0033	CbGpPWpGaD
Ranitidine—SLC22A8—Transmembrane transport of small molecules—CARM1—psoriasis	3.06e-05	0.00314	CbGpPWpGaD
Ranitidine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.05e-05	0.00314	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.04e-05	0.00312	CbGpPWpGaD
Ranitidine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	3e-05	0.00309	CbGpPWpGaD
Ranitidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.99e-05	0.00307	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—CCL20—psoriasis	2.94e-05	0.00302	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—TAGAP—psoriasis	2.9e-05	0.00298	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.78e-05	0.00285	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	2.5e-05	0.00256	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—NDUFA5—psoriasis	2.24e-05	0.0023	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.16e-05	0.00222	CbGpPWpGaD
Ranitidine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	2.08e-05	0.00214	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.08e-05	0.00213	CbGpPWpGaD
Ranitidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.03e-05	0.00209	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—IFNG—psoriasis	2.03e-05	0.00208	CbGpPWpGaD
Ranitidine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.02e-05	0.00208	CbGpPWpGaD
Ranitidine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	1.98e-05	0.00204	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—CYP2S1—psoriasis	1.9e-05	0.00196	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.89e-05	0.00194	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	1.88e-05	0.00194	CbGpPWpGaD
Ranitidine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.77e-05	0.00182	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—NDUFA5—psoriasis	1.74e-05	0.00179	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—CCL20—psoriasis	1.74e-05	0.00178	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.62e-05	0.00166	CbGpPWpGaD
Ranitidine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.62e-05	0.00166	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.55e-05	0.0016	CbGpPWpGaD
Ranitidine—HRH2—GPCR ligand binding—CXCL8—psoriasis	1.55e-05	0.00159	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.53e-05	0.00157	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—CYP2S1—psoriasis	1.48e-05	0.00152	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—NDUFA5—psoriasis	1.34e-05	0.00138	CbGpPWpGaD
Ranitidine—ABCB1—Allograft Rejection—TNF—psoriasis	1.31e-05	0.00135	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—NDUFA5—psoriasis	1.31e-05	0.00135	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.3e-05	0.00134	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.25e-05	0.00129	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—NDUFA5—psoriasis	1.24e-05	0.00127	CbGpPWpGaD
Ranitidine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.22e-05	0.00125	CbGpPWpGaD
Ranitidine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.16e-05	0.0012	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—CYP2S1—psoriasis	1.14e-05	0.00117	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—CYP2S1—psoriasis	1.12e-05	0.00115	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.05e-05	0.00108	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.05e-05	0.00108	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.77e-06	0.001	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—SOCS1—psoriasis	9.56e-06	0.000983	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—CARM1—psoriasis	9.3e-06	0.000955	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—TYK2—psoriasis	9.12e-06	0.000937	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—CYP2S1—psoriasis	8.91e-06	0.000915	CbGpPWpGaD
Ranitidine—HRH2—GPCR downstream signaling—CXCL8—psoriasis	8.74e-06	0.000898	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.65e-06	0.000889	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.33e-06	0.000856	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—NDUFA5—psoriasis	8.08e-06	0.000831	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—CXCL8—psoriasis	7.94e-06	0.000816	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.56e-06	0.000777	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—CARM1—psoriasis	7.22e-06	0.000742	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—APOE—psoriasis	7.06e-06	0.000725	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—LEP—psoriasis	7.06e-06	0.000725	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—CYP2S1—psoriasis	6.87e-06	0.000706	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—NFKBIA—psoriasis	6.58e-06	0.000676	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.48e-06	0.000666	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.99e-06	0.000616	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—CAT—psoriasis	5.72e-06	0.000587	CbGpPWpGaD
Ranitidine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.71e-06	0.000587	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—CARM1—psoriasis	5.58e-06	0.000574	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—CARM1—psoriasis	5.45e-06	0.00056	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—TYK2—psoriasis	5.39e-06	0.000553	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.22e-06	0.000536	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—CARM1—psoriasis	5.13e-06	0.000528	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—CXCL8—psoriasis	4.69e-06	0.000482	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.67e-06	0.00048	CbGpPWpGaD
Ranitidine—HRH2—Signaling by GPCR—IL6—psoriasis	4.46e-06	0.000458	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—APOE—psoriasis	4.44e-06	0.000456	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—CAT—psoriasis	4.44e-06	0.000456	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—JUN—psoriasis	4.36e-06	0.000448	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—CARM1—psoriasis	4.35e-06	0.000447	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—NFKB1—psoriasis	4.2e-06	0.000431	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.07e-06	0.000418	CbGpPWpGaD
Ranitidine—SLC22A1—Metabolism—PPARG—psoriasis	3.87e-06	0.000398	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—VEGFA—psoriasis	3.81e-06	0.000391	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—STAT3—psoriasis	3.77e-06	0.000387	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—APOE—psoriasis	3.45e-06	0.000355	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—CAT—psoriasis	3.43e-06	0.000353	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—CARM1—psoriasis	3.36e-06	0.000345	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—CAT—psoriasis	3.35e-06	0.000344	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—CAT—psoriasis	3.16e-06	0.000324	CbGpPWpGaD
Ranitidine—CYP3A5—Metabolism—PPARG—psoriasis	3.01e-06	0.000309	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—TP53—psoriasis	2.88e-06	0.000296	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—CAT—psoriasis	2.68e-06	0.000275	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—APOE—psoriasis	2.67e-06	0.000274	CbGpPWpGaD
Ranitidine—HRH2—Signaling Pathways—IL6—psoriasis	2.63e-06	0.000271	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—APOE—psoriasis	2.6e-06	0.000268	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—APOE—psoriasis	2.45e-06	0.000252	CbGpPWpGaD
Ranitidine—CYP2C19—Metabolism—PPARG—psoriasis	2.32e-06	0.000239	CbGpPWpGaD
Ranitidine—ABCB1—Metabolism—PPARG—psoriasis	2.27e-06	0.000233	CbGpPWpGaD
Ranitidine—CYP2D6—Metabolism—PPARG—psoriasis	2.14e-06	0.00022	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—APOE—psoriasis	2.08e-06	0.000214	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—CAT—psoriasis	2.06e-06	0.000212	CbGpPWpGaD
Ranitidine—CYP1A2—Metabolism—PPARG—psoriasis	1.81e-06	0.000186	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—APOE—psoriasis	1.6e-06	0.000165	CbGpPWpGaD
Ranitidine—CYP3A4—Metabolism—PPARG—psoriasis	1.4e-06	0.000144	CbGpPWpGaD
